Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Follow Us
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

Pharmaceutical Pipeline

Download Report

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

Therapeutic Area
Select All Reset
Changes
Oncology
25 of 53 Total Indications

Oncology

amivantamab / lazertinib

Non Small Cell Lung Cancer 11
Phase III US
Phase III EU

BALVERSA (erdafitinib)

Urothelial cancer 7
Approved 4/19 US
Phase III EU

BALVERSA (erdafitinib)

Tumor Agnostic 7
Phase II US
Phase II EU

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer 7
Phase II US
Phase II EU

ciltacabtagene autoleucel (BCMA CAR-T)

Relapsed refractory multiple myeloma 9
Filed 3/21 US
Filed 4/21 EU

ciltacabtagene autoleucel (BCMA CAR-T)

Relapsed refractory multiple myeloma w/1-3 PL 9
Phase III US
Phase III EU

DARZALEX (daratumumab)

Relapsed Refractory Multiple Myeloma w/PomDex 5
Approved 7/21 US
Approved 6/21 EU

DARZALEX (daratumumab)

Amyloidosis (ANDROMEDA) 5
Approved 1/21 US
Approved 6/21 EU

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001) 5
Phase III US
Phase III EU

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (CEPHEUS) 5
Phase III US
Phase III EU

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (PERSEUS) 5
Phase III US
Phase III EU

ERLEADA (apalutamide)

Localized prostate cancer
Phase III US
Phase III EU

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)
Phase III US
Phase III EU

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE) 6
Phase III US
Phase III EU

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (SELENE) 6
Phase III US
Phase III EU

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) 6
Phase III US
Phase III EU

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO) 6
Phase III US
Phase III EU

niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone 8
Phase III US
Phase III EU

niraparib / abiraterone acetate

M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone
Phase III US
Phase III EU

RIS/gemcitabine plus cetrelimab

Muscle non invasive bladder cancer
Phase II US
Phase II EU

RIS/gemcitabine plus cetrelimab

Non-muscle invasive bladder cancer
Phase III US
Phase III EU

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer 11
Approved 5/21 US
Filed 1/21 US

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy 11
Phase III US
Phase III EU

talquetamab (GPRC5D/CD3)

Relapsed refractory multiple myeloma 11
Phase II US
Phase II EU

teclistamab (BCMA/CD3)

Relapsed refractory multiple myeloma 11
Phase II US
Phase II EU
This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer HealthCare; (5) DARZALEX licensed from Genmab A/S; (6) IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; (7) BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; (8) Niraparib licensed from Tesaro; (9) BCMA CAR-T licensed from Legend Biotech; (10) Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; (11) DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab);
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue